Active Ingredient History
Rubitecan is an oral topoisomerase inhibitor, developed by SuperGen. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Colorectal Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Hamartoma (Phase 2)
Intestinal Neoplasms (Phase 2)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 2)
Melanoma (Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 3)
Prostatic Neoplasms (Phase 2)
Sarcoma (Phase 2)
Stomach Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterus (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue